Compare ATS & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATS | AVDL |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 2023 | 1996 |
| Metric | ATS | AVDL |
|---|---|---|
| Price | $29.33 | $21.56 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $35.00 | $19.14 |
| AVG Volume (30 Days) | 115.9K | ★ 1.5M |
| Earning Date | 02-04-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,930,283,080.00 | $248,517,000.00 |
| Revenue This Year | $16.92 | $65.47 |
| Revenue Next Year | $5.13 | $30.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 79.88 |
| 52 Week Low | $20.90 | $6.38 |
| 52 Week High | $32.73 | $23.57 |
| Indicator | ATS | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 60.82 |
| Support Level | $28.96 | $21.51 |
| Resistance Level | $29.92 | $21.65 |
| Average True Range (ATR) | 0.93 | 0.07 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 55.86 | 66.67 |
ATS Corp is a Canada-based company that provides automation systems. The company designs and builds customized automated manufacturing and testing systems for customers, and provides pre- and post-automation services. The company's products comprise conveyor systems, automated electrified monorails, tray handlers, laser systems, and other hardware and software products. The company also provides pre-automation solutions, including strategic direction and planning services, as well as aftermarket support. The company's clients come from the life sciences, food and beverage transportation, consumer products and electronics, and energy sectors. The company generates the majority of its sales from the North American and European markets.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.